2015 American Transplant Congress
Detection of Donor Specific HLA-Ab (DSA) Against Native HLA Molecules Expressed On Donor Cell Surface to Eliminate False Positive DSA in Luminex Single Antigen Beads (LMX-SAB)
Pathology, Stanford University, Palo Alto, CA.
Introduction:The LMX-SAB has been extensively used for DSA virtual crossmatch (VXM) to predict actual crossmatch (AXM). The extreme pH and harsh chemical reaction conditions used…2015 American Transplant Congress
Role of CMV, BKV, and Immunosupression Non-Adherence in Early and Late De Novo Donor Specific Anti-HLA Antibody Development and Outcomes
This analysis aims to identify appropriate de novo DSA (dnDSA) screening points and delineate the post-transplant (txp) scenarios preceding dnDSA development to aid in clinical…2015 American Transplant Congress
A Novel DSA Flow Cytometer Crossmatch (DSA-FXM) to Eliminate Ambiguous Auto- and Allo-FXM Results
Pathology, Stanford University, Palo Alto, CA.
Introduction:Though usually rejected on theoretical grounds, a positive Auto-FXM could result from either or both auto-reactive non-HLA or HLA-antibodies (Ab). Furthermore, a positive Auto-FXM serum…2015 American Transplant Congress
Isolated Microcirculation Inflammation Negatively Impacts Renal Graft Function at 5 Years
BACKGROUND: Microcirculation inflammation (MI, ie: glomerulitis (g) and peritubular capillaritis (ptc)) associated with anti-HLA Donor Specific Antibody (DSA) with or without C4d deposits in ptc…2015 American Transplant Congress
Outcomes Following Kidney Transplant With Low Level Positive Flow Cytometric Crossmatch
Introduction: Highly-sensitized kidney transplant (KTx) candidates have difficulty finding a negative crossmatch donor. KTx with low level positive crossmatch might be the next best option.…2015 American Transplant Congress
Immune Response to Kidney and Pancreas Self-Antigens Are Associated With Antibody Mediated Rejection in Simultaneous Kidney Pancreas Transplants
Background: Simultaneous kidney-pancreas transplantation (SKP Tx) is performed as treatment option for type-1 diabetes with end stage kidney diseases. Though allograft survival was improved with…2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…2015 American Transplant Congress
The Differential Effect of HLA-DQ Mismatching on Renal Allograft Survival in Zero HLA-A,B,DR Mismatched Deceased Donor Transplants
1University of Florida, Gainesville; 2University of Kansas, Kansas City.
The role of HLA-DQ matching in renal graft survival is not well understood and difficult to interpret in the presence of other HLA antigen mismatches.…2015 American Transplant Congress
Chronic Active Antibody Mediated Rejection (cABMR): Treatment, Outcomes and Predictors of Graft Loss in a Large Case Series
1University of Wisconsin, Madison, WI; 2University of Michigan, Ann Arbor, MI.
Background: CABMR is a barrier to long-term kidney allograft survival. There is little information on the treatment and outcomes of kidney transplant recipients with cABMR.Methods:…2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…
American Transplant Congress abstracts